TABLE 5.
Impact of antibiotic resistance on the eradication rate in the PP populationa
| Group (n)b | Eradication rate by resistance typec |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amoxicillin |
Clarithromycin |
Tetracycline |
Dual |
||||||||
| Yes | No | P | Yes | No | P | Yes | No | Yes | No | P | |
| LR-BAC (68) | 2/2 (100) | 62/66 (93.9) | 1.000 | 12/14 (85.7) | 52/54 (96.3) | 0.185 | 0 | 64/68 (94.1) | 1 (100) | 63/67 (94.0) | |
| LR-BAT (63) | 2/2 (100) | 54/61 (88.5) | 1.000 | 14/14 (100) | 42/49 (85.7) | 0.333 | 0 | 56/63 (88.9) | 2/2 (100) | 54/61 (88.5) | 1.000 |
| HR-BAC (66) | 1/1 (100) | 61/65 (93.8) | 6/6 (100) | 56/60 (93.3) | 1.000 | 1/1 (100) | 61/65 (93.8) | 1/1 (100) | 61/65 (93.8) | ||
| HR-BAT (64) | 5/5 (100) | 55/59 (93.2) | 1.000 | 14/14 (100) | 46/50 (92.0) | 0.568 | 1/1 (100) | 59/63 (93.7) | 3 (100) | 57/61 (93.4) | 1.000 |
a
PP, per protocol.
b
LR-BAC group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; LR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline; HR-BAC group, rabeprazole at 20 mg b.i.d. plus bismuth, amoxicillin, and clarithromycin; HR-BAT group, rabeprazole at 10 mg b.i.d. plus bismuth, amoxicillin, and tetracycline.
c
Values are the number of eradications/total number of patients (percentage).